Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu
  • quotes

  • charts

  • technicals

  • company

Regen Biopharma Inc (RGBPP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0251 unch
on 05/25/18
0.0400 -37.25%
on 05/11/18
-0.0099 (-28.29%)
since 04/24/18
3-Month
0.0251 unch
on 05/25/18
0.0750 -66.53%
on 03/08/18
-0.0209 (-45.43%)
since 02/23/18
52-Week
0.0200 +25.50%
on 07/31/17
0.0900 -72.11%
on 11/21/17
-0.0127 (-33.60%)
since 05/25/17

Most Recent Stories

More News
Entest Group, Inc. Declares Property Dividend of 3,000,000 Common Shares of Zander Therapeutics Inc.

On May 10, 2018, Entest Group, Inc. (OTC: ETNI) declared the distribution on a pro rata basis as a dividend in kind of 3,000,000 of the common shares of Zander Therapeutics, Inc., par value $0.0001, currently...

RGBP : 0.0250 (unch)
RGBPP : 0.0251 (-0.40%)
ETNI : 0.0800 (+14.29%)
Regen BioPharma, Inc. Nears Completion of Optimizing its Lead NR2F6 Small Molecule Agonist

SAN DIEGO , March 21, 2018 /PRNewswire/ --

RGBP : 0.0250 (unch)
RGBPP : 0.0251 (-0.40%)
Regen BioPharma, Inc. Nears Completion of Optimizing its Lead NR2F6 Small Molecule Agonist

Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has been methodically optimizing small molecules that bind to, and activate, the NR2F6 nuclear receptor. The process is close to completion, with the...

RGBP : 0.0250 (unch)
RGBPP : 0.0251 (-0.40%)
Regen BioPharma, Inc.'s Medicinal Chemistry Program has Identified Additional Compounds That Activate NR2F6

Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) continues to develop small molecule drugs that activate NR2F6 and has identified a key structural element whose presence in small molecules seems to...

RGBP : 0.0250 (unch)
RGBPP : 0.0251 (-0.40%)
Regen BioPharma, Inc.'s Medicinal Chemistry Program has Identified Additional Compounds That Activate NR2F6

SAN DIEGO , January 17, 2018 /PRNewswire/ --

RGBP : 0.0250 (unch)
RGBPP : 0.0251 (-0.40%)
Regen BioPharma, Inc. Files Additional Composition of Matter Patent Application on NR2F6-Modulating Small Molecules

Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) today announced filing a patent application covering composition of matter and methods of use related to molecules identified in its small molecule...

RGBP : 0.0250 (unch)
RGBPP : 0.0251 (-0.40%)
Regen BioPharma, Inc. Files Additional Composition of Matter Patent Application on NR2F6-Modulating Small Molecules

SAN DIEGO , December 11, 2017 /PRNewswire/ --

RGBP : 0.0250 (unch)
RGBPP : 0.0251 (-0.40%)
Regen BioPharma, Inc. Begins In Vivo Assessment of Small Molecule Agonists to NR2F6 Nuclear Receptor

SAN DIEGO, California , November 27, 2017 /PRNewswire/ --

RGBP : 0.0250 (unch)
RGBPP : 0.0251 (-0.40%)
Regen BioPharma, Inc. Begins In Vivo Assessment of Small Molecule Agonists to NR2F6 Nuclear Receptor

Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has initiated in vivo and ex vivo assessments to determine the effects of some of the Company's NR2F6 small molecule agonists in live rats and in tissues...

RGBP : 0.0250 (unch)
RGBPP : 0.0251 (-0.40%)
Cancer Immunotherapy Technology Projected to Create Further Growth

According to data provided by Allied Market Research, the global cancer immunotherapy market is expected to grow to $117.14 billion by 2022, growing at a CAGR of 14.5 percent from the time period of 2016...

CLDX : 0.63 (-1.25%)
ARQL : 5.15 (+13.69%)
RGBP : 0.0250 (unch)
RGBPP : 0.0251 (-0.40%)
ECYT : 13.33 (-5.19%)
CASI : 6.79 (-2.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More Share

Trade RGBPP with:

Key Turning Points

2nd Resistance Point 0.0251
1st Resistance Point 0.0251
Last Price 0.0251
1st Support Level 0.0251
2nd Support Level 0.0251

See More

52-Week High 0.0900
Fibonacci 61.8% 0.0633
Fibonacci 50% 0.0550
Fibonacci 38.2% 0.0467
Last Price 0.0251
52-Week Low 0.0200

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar